These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 10894285)

  • 61. Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance.
    Pattery T; Verlinden Y; De Wolf H; Nauwelaers D; Van Baelen K; Van Houtte M; Mc Kenna P; Villacian J
    Intervirology; 2012; 55(2):138-46. PubMed ID: 22286884
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach.
    Jenwitheesuk E; Samudrala R
    Antivir Ther; 2005; 10(1):157-66. PubMed ID: 15751773
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Persistence of mutations during replication of an HIV library containing combinations of selected protease mutations.
    Song W; Maeda Y; Tenpaku A; Harada S; Yusa K
    Antiviral Res; 2004 Mar; 61(3):173-80. PubMed ID: 15168798
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors.
    Talbot A; Grant P; Taylor J; Baril JG; Liu TF; Charest H; Brenner B; Roger M; Shafer R; Cantin R; Zolopa A
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2473-9. PubMed ID: 20368406
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Côte d'Ivoire.
    Adjé-Touré C; Celestin B; Hanson D; Roels TH; Hertogs K; Larder B; Diomande F; Peeters M; Eholié S; Lackritz E; Chorba T; Nkengasong JN
    AIDS; 2003 Jul; 17 Suppl 3():S23-9. PubMed ID: 14565606
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.
    Rusconi S; La Seta Catamancio S; Citterio P; Kurtagic S; Violin M; Balotta C; Moroni M; Galli M; d'Arminio-Monforte A
    Antimicrob Agents Chemother; 2000 May; 44(5):1328-32. PubMed ID: 10770770
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Analysis of the protease sequences of HIV-1 infected individuals after Indinavir monotherapy.
    Sa-Filho DJ; Costa LJ; de Oliveira CF; Guimarães AP; Accetturi CA; Tanuri A; Diaz RS
    J Clin Virol; 2003 Oct; 28(2):186-202. PubMed ID: 12957189
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Acquisition of multi-PI (protease inhibitor) resistance in HIV-1 in vivo and in vitro.
    Yusa K; Harada S
    Curr Pharm Des; 2004; 10(32):4055-64. PubMed ID: 15579087
    [TBL] [Abstract][Full Text] [Related]  

  • 69. HIV-1 protease mutations and protease inhibitor cross-resistance.
    Rhee SY; Taylor J; Fessel WJ; Kaufman D; Towner W; Troia P; Ruane P; Hellinger J; Shirvani V; Zolopa A; Shafer RW
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4253-61. PubMed ID: 20660676
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Collinearity of protease mutations in HIV-1 samples with high-level protease inhibitor class resistance.
    Babrzadeh F; Varghese V; Pacold M; Liu TF; Nyrén P; Schiffer C; Fessel WJ; Shafer RW
    J Antimicrob Chemother; 2013 Feb; 68(2):414-8. PubMed ID: 23085775
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
    Youle M
    J Antimicrob Chemother; 2007 Dec; 60(6):1195-205. PubMed ID: 17890281
    [TBL] [Abstract][Full Text] [Related]  

  • 72. HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G.
    Palma AC; Covens K; Snoeck J; Vandamme AM; Camacho RJ; Van Laethem K
    J Antimicrob Chemother; 2012 May; 67(5):1075-9. PubMed ID: 22331593
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Reduced antiretroviral drug susceptibility among patients with primary HIV infection.
    Little SJ; Daar ES; D'Aquila RT; Keiser PH; Connick E; Whitcomb JM; Hellmann NS; Petropoulos CJ; Sutton L; Pitt JA; Rosenberg ES; Koup RA; Walker BD; Richman DD
    JAMA; 1999 Sep 22-29; 282(12):1142-9. PubMed ID: 10501117
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors.
    Shafer RW; Hsu P; Patick AK; Craig C; Brendel V
    J Virol; 1999 Jul; 73(7):6197-202. PubMed ID: 10364383
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Protease inhibitor-resistant HIV-1 from patients with preserved CD4 cell counts is cytopathic in activated CD4 T lymphocytes.
    Liegler TJ; Hayden MS; Lee KH; Hoh R; Deeks SG; Granta RM
    AIDS; 2001 Jan; 15(2):179-84. PubMed ID: 11216925
    [TBL] [Abstract][Full Text] [Related]  

  • 77.
    Datir R; Kemp S; El Bouzidi K; Mlchocova P; Goldstein R; Breuer J; Towers GJ; Jolly C; Quiñones-Mateu ME; Dakum PS; Ndembi N; Gupta RK
    mBio; 2020 Nov; 11(6):. PubMed ID: 33144375
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.
    Kozal MJ; Hullsiek KH; Leduc R; Novak RM; MacArthur RD; Lawrence J; Baxter JD;
    Antivir Ther; 2006; 11(4):457-63. PubMed ID: 16856619
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Primary drug resistance in antiretroviral-naïve injection drug users.
    Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
    Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures.
    Campo RE; Moreno JN; Suarez G; Miller N; Kolber MA; Holder DJ; Shivaprakash M; DeAngelis DM; Wright JL; Schleif WA; Emini EA; Condra JH
    AIDS; 2003 Sep; 17(13):1933-9. PubMed ID: 12960826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.